Literature DB >> 28754237

Treatment of larva migrans syndrome with long-term administration of albendazole.

Amy Hombu1, Ayako Yoshida1, Taisei Kikuchi1, Eiji Nagayasu1, Mika Kuroki1, Haruhiko Maruyama2.   

Abstract

BACKGROUND: Larva migrans syndrome is a food-borne parasitic disease in humans, caused by accidental ingestion of eggs or larvae of ascarid nematodes, namely, Toxocara canis, Toxocara cati, or Ascaris suum, the roundworms commonly found in the intestines of dogs, cats and pigs respectively. When a patient is diagnosed as having larva migrans syndrome, oral-administration of albendazole is recommended, however, the regimen remains controversial worldwide. In Japan, the duration of albendazole administration is longer than those of European and North American countries. The purpose of this study was to assess the efficacy and safety of long-term administration treatment of albendazole for larva migrans syndrome.
METHODS: From 2004 to 2014, our laboratory was involved in the diagnosis of 758 larva migrans syndrome cases, of which 299 cases could be followed up after the treatment. We analyzed these 299 follow-up cases on the ELISA results before and after the treatment as well as on anthelmintic used, dose and duration of medication, clinical findings, and side effects, recorded on a consultation sheet provided by the attending physicians. We have 288 cases as the subjects of this study.
RESULTS: Albendazole represented a 78.0% efficacy rate. The side effects represented 15.0% in using albendazole alone cases; however, the side effects were mild to moderate and there were no severe cases reported.
CONCLUSIONS: The long-term administration treatment of albendazole is safe and effective for larva migrans syndrome.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Albendazole; Ascaris suum; Larva migrans syndrome; Toxocara canis; Toxocara cati

Mesh:

Substances:

Year:  2017        PMID: 28754237     DOI: 10.1016/j.jmii.2017.07.002

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  6 in total

1.  Bone marrow mesenchymal stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model.

Authors:  Faten A M Abo-Aziza; Abdel Kader A Zaki; Ahmed I Alajaji; Saleh M Al Barrak
Journal:  Vet World       Date:  2021-02-08

Review 2.  The prevalence of foodborne parasites in raw vegetables in Iran: a comprehensive systematic review and meta-analysis.

Authors:  Behnam Bahramian; Asma Afshari; Behzad Kiani; Mahmood Alizadeh Sani; Mohammad Hashemi
Journal:  J Environ Health Sci Eng       Date:  2021-08-27

3.  Toxocariasis Suspected of Having Infiltrated Directly from the Liver to the Lung through the Diaphragm.

Authors:  Masaki Kakimoto; Masayuki Murata; Fujiko Mitsumoto-Kaseida; Eiichi Ogawa; Yuji Matsumoto; Akira Kusaga; Kazuhiro Toyoda; Takeo Hayashi; Kazuya Ura; Keishi Kanno; Norihiro Furusyo; Susumu Tazuma
Journal:  Intern Med       Date:  2019-06-07       Impact factor: 1.271

4.  Therapy and Prevention for Human Toxocariasis.

Authors:  Jean-François Magnaval; Emilie Bouhsira; Judith Fillaux
Journal:  Microorganisms       Date:  2022-01-22

Review 5.  Toxocariasis: a silent threat with a progressive public health impact.

Authors:  Jia Chen; Quan Liu; Guo-Hua Liu; Wen-Bin Zheng; Sung-Jong Hong; Hiromu Sugiyama; Xing-Quan Zhu; Hany M Elsheikha
Journal:  Infect Dis Poverty       Date:  2018-06-13       Impact factor: 4.520

6.  Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update.

Authors:  Jong-Yil Chai; Bong-Kwang Jung; Sung-Jong Hong
Journal:  Korean J Parasitol       Date:  2021-06-21       Impact factor: 1.341

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.